Tarsus Pharmaceuticals, Inc. TARS
72.64 USD -0.68 (-0.93%)
At closeNov 3, 2026, 6:31 PM EST
72.64 0.00 0.00%
After hours · Nov 3, 6:31 PM ET
70.40 Day range 75.20
53.89 52-week range 91.53
- YTD
- -11.28%
- 1 year
- +4.08%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 98.89 +36.1% upside
Now 72.64
- Target (low)
- 84.00
- Target (mean)
- 98.89
- Target (high)
- 116.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
- Strong buy1
- Buy9
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 10
- 1 month ago 10
- 2 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.77 | -2.01 – -1.46 | -0.30 | -490.0% | 190.78M | +60.7% | 3 |
| Next quarter | -4.82 | -9.57 – -0.07 | -0.20 | -2310.0% | 210.89M | +39.0% | 2 |
| Current year | -5.79 | -11.63 – -2.52 | -1.59 | -264.4% | 736.88M | +63.3% | 3 |
| Next year | -0.50 | -1.59 – 1.04 | -5.79 | +91.4% | 920.04M | +24.9% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 8, 2026 | Jefferies | Maintained | Buy | Buy |
| Aug 12, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Jul 31, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Jul 21, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jul 9, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 4, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 25, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Feb 25, 2026 | Guggenheim | Maintained | Buy | Buy |
| Dec 9, 2025 | Barclays | Initiated | — | Overweight |
| Nov 20, 2025 | Mizuho | Initiated | — | Outperform |
| Nov 5, 2025 | Guggenheim | Maintained | Buy | Buy |
| Oct 20, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 5, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| May 2, 2025 | Guggenheim | Maintained | Buy | Buy |
| Mar 6, 2025 | Jefferies | Maintained | Buy | Buy |
| Feb 26, 2025 | Guggenheim | Maintained | Buy | Buy |
| Feb 26, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 26, 2025 | Barclays | Maintained | Overweight | Overweight |
| Feb 24, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Feb 10, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Jan 27, 2025 | Barclays | Maintained | Overweight | Overweight |
| Jan 22, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Nov 15, 2024 | Goldman Sachs | Maintained | Neutral | Neutral |
| Nov 14, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Aug 9, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| May 13, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 10, 2024 | Barclays | Maintained | Overweight | Overweight |
| May 9, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Mar 6, 2024 | Jefferies | Maintained | Buy | Buy |
| Feb 29, 2024 | Goldman Sachs | Maintained | Neutral | Neutral |